Vertex Pharmaceuticals Inc

More Details of Vertex Pharmaceuticals Inc Company

Company Info

Company codeVRTX

Company nameVertex Pharmaceuticals Inc

IPO dateJul 24, 1991

Founded at1989

CEODr. Reshma Kewalramani

Number of employees6100

Security typeOrdinary Share

Fiscal year-endJul 24

Address50 Northern Avenue

CityBOSTON

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02210

Phone16173416393

Websitehttps://www.vrtx.com/

Company codeVRTX

IPO dateJul 24, 1991

Founded at1989

Company Executives

Name

Name/Position

Position

Shareholding

Change

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.66K

+40.46%

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

30.14K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.25K

+59.69%

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

17.10K

+342.84%

Mr. Lloyd A. Carney

Independent Director

6.31K

+18.82%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.43K

--

Ms. Diana L. Mckenzie

Independent Director

1.47K

-10.17%

Mr. Michel Lagarde

Independent Director

1.13K

--

Ms. Kristen Ambrose

Senior Vice President, Chief Accounting Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. Bruce I. Sachs

Lead Independent Director

40.00K

--

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.66K

+40.46%

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

30.14K

--

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

25.25K

+59.69%

Mr. Stuart A. Arbuckle

Chief Operating Officer, Executive Vice President

17.10K

+342.84%

Mr. Lloyd A. Carney

Independent Director

6.31K

+18.82%

Revenue Breakdown

Currency: USDUpdate time: Wed, Mar 5

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

TRIKAFTA

10.23B

92.90%

Other CF products

781.50M

7.09%

By RegionUSD

Name

Revenue

Proportion

United States

6.68B

60.66%

Europe

3.45B

31.34%

Other

881.30M

7.99%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

TRIKAFTA

10.23B

92.90%

Other CF products

781.50M

7.09%

Shareholder

Update time: Fri, Feb 21

Shareholder Statistics

Type

Shareholder Statistics

Shareholder

Proportion

Capital World Investors

11.03%

The Vanguard Group, Inc.

9.01%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.64%

Shareholder Statistics

Shareholder

Proportion

Capital World Investors

11.03%

The Vanguard Group, Inc.

9.01%

BlackRock Institutional Trust Company, N.A.

5.57%

State Street Global Advisors (US)

4.66%

Capital Research Global Investors

4.06%

Other

65.64%

Type

Shareholder

Proportion

Investment Advisor

49.08%

Investment Advisor/Hedge Fund

37.63%

Pension Fund

2.66%

Research Firm

2.13%

Bank and Trust

1.87%

Hedge Fund

1.44%

Sovereign Wealth Fund

1.43%

Holding Company

0.19%

Individual Investor

0.12%

Other

3.41%

Institutional Shareholding

Update time: Sun, Jan 19

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q1

2803

248.60M

96.81%

-2.22M

2024Q4

2877

248.75M

96.87%

-2.25M

2024Q3

2786

247.86M

96.18%

-4.19M

2024Q2

2747

248.35M

96.27%

-4.14M

2024Q1

2680

247.62M

95.87%

-4.47M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.88M

96.55%

-7.10M

2023Q1

2468

250.11M

97.13%

-4.73M

2022Q4

2454

248.59M

96.73%

-7.79M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

Capital World Investors

28.32M

11.03%

+1.51M

+5.65%

Dec 31, 2024

The Vanguard Group, Inc.

23.14M

9.01%

+102.47K

+0.44%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

14.32M

5.57%

-90.57K

-0.62%

Dec 31, 2024

State Street Global Advisors (US)

11.97M

4.66%

+163.15K

+1.38%

Dec 31, 2024

Capital Research Global Investors

10.42M

4.06%

+1.42M

+15.84%

Dec 31, 2024

Fidelity Management & Research Company LLC

9.10M

3.54%

-1.25M

-12.06%

Dec 31, 2024

Wellington Management Company, LLP

5.91M

2.3%

+1.11M

+23.28%

Dec 31, 2024

Geode Capital Management, L.L.C.

5.64M

2.19%

-287.65K

-4.84%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

5.22M

2.03%

+92.09K

+1.79%

Dec 31, 2024

JP Morgan Asset Management

4.61M

1.79%

-403.92K

-8.04%

Dec 31, 2024

Related ETFs

Update time: 16 hours ago

Name

Proportion

Future Fund Active ETF

13.69%

VanEck Biotech ETF

11.53%

ProShares Ultra Nasdaq Biotechnology

8.36%

Invesco Nasdaq Biotechnology ETF

7.92%

Tema Neuroscience and Mental Health ETF

7.19%

iShares Biotechnology ETF

6.84%

Natixis Loomis Sayles Focused Growth ETF

5.03%

Franklin Genomic Advancements ETF

4.8%

Tema Cardiovascular and Metabolic ETF

4.37%

First Trust NYSE Arca Biotechnology Index Fund

3.64%

Future Fund Active ETF

Proportion13.69%

VanEck Biotech ETF

Proportion11.53%

ProShares Ultra Nasdaq Biotechnology

Proportion8.36%

Invesco Nasdaq Biotechnology ETF

Proportion7.92%

Tema Neuroscience and Mental Health ETF

Proportion7.19%

iShares Biotechnology ETF

Proportion6.84%

Natixis Loomis Sayles Focused Growth ETF

Proportion5.03%

Franklin Genomic Advancements ETF

Proportion4.8%

Tema Cardiovascular and Metabolic ETF

Proportion4.37%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.64%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

489.190USD

Vertex Pharmaceuticals Inc

489.190

Overview

Company